EQS Group-Ad-hoc: Polyphor AG / Key word(s): Annual Results 
Polyphor to present full-year 2020 financial results on March 5 
26-Feb-2021 / 07:30 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Allschwil, Switzerland, February 26, 2021 
Polyphor to Present Full-Year 2020 Financial Results on March 5 
Polyphor AG (SIX: POLN) announced today that it will publish its full-year financial results for 2020 on March 5 at 
7:30am CET. 
Gökhan Batur (CEO) and Hernan Levett (CFO) will host an earnings call at 2:00pm CET, together with Frank Weber (CMDO), 
Daniel Obrecht (CSO) and Johann Zimmermann (Head of Oncology Research). To access the earnings call, please use the 
following details: 
Switzerland: +41 44 580 65 22 
Germany: +49 69 201744 220 
France: +33 170 709 502 
Italy: +39 02 36 00 66 63 
United Kingdom: +44 203 009 2470 
United States: +1 877 423 0830 
Event Title: Polyphor Ltd. - Corporate Update and 2020 Financial Results 
Confirmation code: 86382921# 
The presentation will also be available via webcast: https://www.webcast-eqs.com/polyphor20210305 
After the call, the presentation will be available via the above link. 
For further information please contact: 
For Investors: 
Hernan Levett           Mary-Ann Chang 
Chief Financial Officer LifeSci Advisors 
Polyphor Ltd.           Tel: +44 7483 284 853 
+41 61 567 16 00        mchang@lifesciadvisors.com 
IR@polyphor.com For Media: Bernhard Schmid LifeSci Advisors +41 44 447 12 21 bschmid@lifesciadvisors.com

About Polyphor Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Polyphor AG 
              Hegenheimermattweg 125 
              4123 Allschwil 
              Switzerland 
Phone:        +41 61 567 1600 
Fax:          +41 61 567 1601 
E-mail:       info@polyphor.com 
Internet:     www.polyphor.com 
ISIN:         CH0106213793 
Valor:        POLN 
Listed:       SIX Swiss Exchange 
EQS News ID:  1171330 
 
End of Announcement EQS Group News Service 
=------------

1171330 26-Feb-2021 CET/CEST

(END) Dow Jones Newswires

February 26, 2021 01:33 ET (06:33 GMT)